MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.14. On average, analysts expect MIRA Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
MIRA Pharmaceuticals Stock Performance
NASDAQ:MIRA opened at $0.83 on Friday. The company has a market cap of $14.03 million, a PE ratio of -1.49 and a beta of 2.05. The stock has a 50-day simple moving average of $1.10 and a 200 day simple moving average of $1.21. MIRA Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $5.01.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Read More
- Five stocks we like better than MIRA Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Technology Stocks Explained: Here’s What to Know About Tech
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- What is a penny stock? A comprehensive guide
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.